Thrivorship Program for Traumatic Injury Survivors

Overseen By Marissa A Boeck, MD, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of California, San Francisco

Disqualifiers: Under 18, Deceased, Unable consent

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

25 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Human-Centered Injury Thrivorship Pathway?

Research shows that using a structured care plan, like a clinical pathway, can improve outcomes for trauma patients by enhancing resource use, care continuity, and reducing hospital stay. Multidisciplinary approaches have also been effective in improving recovery in trauma patients, suggesting that similar methods could benefit those in the Thrivorship Program. ^{1 2 3 4 5}

Is the Thrivorship Program for Traumatic Injury Survivors generally safe for humans?

The research articles reviewed focus on identifying and preventing adverse events (unintended, potentially harmful events) in trauma care, which suggests that safety is a key concern in trauma treatment. However, specific safety data for the Thrivorship Program itself is not provided in these articles. ^{6 7 8 9 10}

What makes the Human-Centered Injury Thrivorship Pathway treatment unique for traumatic injury survivors?

The Human-Centered Injury Thrivorship Pathway is unique because it focuses on a holistic, person-centered approach that integrates multiple specialties and emphasizes patient and family-centered care, wellness interventions, and healing environments, which are not typically part of standard treatments for traumatic injuries. ^{11 12 13 14 15}

What is the purpose of this trial?

The goal of this clinical trial is to pilot and evaluate a human-centered injury thrivorship pathway in injury survivors. The main question it aims to answer is: • Is the pathway appropriate, acceptable, and feasible to meet the medical and social needs of injury survivors? Injury survivors will be purposively sampled to enroll in the pathway and asked to participate in in-depth interviews and their use of pathway resources will be tracked.

Research Team

Marissa A Boeck, MD, MPH

Principal Investigator

University of California, San Francisco

Eligibility Criteria

This trial is for individuals who have survived physical trauma and are navigating their recovery. It's designed to assess a new support pathway tailored to both medical and social needs of these survivors. Participants should be willing to engage in interviews and allow tracking of their use of the provided resources.

Inclusion Criteria

Patient must be a San Francisco resident or unhoused in San Francisco

I understand the details of the clinical trial and can consent to participate.

I must stay in the hospital for at least 24 hours.

Exclusion Criteria

Patient must have deceased during index hospitalization

I am unable to understand and give consent for my own treatment.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pathway Enrollment

Participants are enrolled in the human-centered injury thrivorship pathway and participate in in-depth interviews

8-12 weeks

Follow-up

Participants are monitored for pathway resource utilization and engagement

up to 1 year

Treatment Details

Interventions

• Human-Centered Injury Thrivorship Pathway

Trial Overview The study is testing a 'Human-Centered Injury Thrivorship Pathway' which aims to help injury survivors with their recovery process. The focus is on determining if this pathway is suitable, well-received, and practical for addressing the comprehensive needs of these individuals.

Participant Groups

Group I: Injury Thrivorship Pathway Experimental Treatment 1 Intervention

Enrollment in the human-centered injury thrivorship pathway.

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials

2,636

Recruited

19,080,000+

National Center for Advancing Translational Sciences (NCATS)

Collaborator

Trials

394

Recruited

404,000+

Findings from Research

In a study of 193 pediatric patients with severe traumatic brain injury (sTBI), 53% experienced at least one adverse event (AE), highlighting the high risk of complications in this vulnerable population.

The most common AE was decubitus ulcers, and patients with AEs had longer hospital stays and higher costs, indicating that identifying and preventing AEs can improve patient safety and reduce healthcare expenses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Identification of adverse events in pediatric severe traumatic brain injury patients to target evidence-based prevention for increased performance improvement and patient safety. Charyk Stewart, T., Luong, K., Alharfi, I., et al.[2021]

In a Level II trauma center, 86% of adult trauma patients enrolled in the Trauma Resilience and Recovery Program (TRRP), indicating strong initial engagement despite fewer resources compared to Level I centers.

However, only 30% of patients completed mental health screenings during follow-up, suggesting a need for program adaptations to enhance ongoing engagement and address mental health needs more effectively.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Implementation of a stepped care program to address posttraumatic stress disorder and depression in a Level II trauma center. Espeleta, HC., Litvitskiy, NS., Higgins, K., et al.[2023]

References

1. United States pubmed.ncbi.nlm.nih.gov

A systems approach to multidimensional critical paths. [2004]

2. United States pubmed.ncbi.nlm.nih.gov

Multidisciplinary Care Pathway Improves Outcomes in Geriatric Trauma Patients. [2022]

3. United States pubmed.ncbi.nlm.nih.gov

Use of an acute spinal cord injury clinical pathway. [2019]

4. England pubmed.ncbi.nlm.nih.gov

The effectiveness of clinical pathway-directed care on hospitalisation-related outcomes in patients with severe traumatic brain injury: A quasi-experimental study. [2019]

5. United States pubmed.ncbi.nlm.nih.gov

The 12-Month Effects of the Trauma Collaborative Care Intervention: A Nonrandomized Controlled Trial. [2023]

6. Netherlands pubmed.ncbi.nlm.nih.gov

Identification of adverse events in pediatric severe traumatic brain injury patients to target evidence-based prevention for increased performance improvement and patient safety. [2021]

7. Germany pubmed.ncbi.nlm.nih.gov

The Australian Trauma Registry (ATR): a leading clinical quality registry. [2023]

8. Netherlands pubmed.ncbi.nlm.nih.gov

Improving recovery-Learning from patients' experiences after injury: a qualitative study. [2021]

9. England pubmed.ncbi.nlm.nih.gov

Incidence and preventability of adverse events in the emergency room of an orthopaedic traumatologic surgery unit. [2019]

10. United States pubmed.ncbi.nlm.nih.gov

Posttraumatic concerns: a patient-centered approach to outcome assessment after traumatic physical injury. [2022]

11. Netherlands pubmed.ncbi.nlm.nih.gov

Implementation of a stepped care program to address posttraumatic stress disorder and depression in a Level II trauma center. [2023]

12. United States pubmed.ncbi.nlm.nih.gov

Polytrauma Transitional Rehabilitation in the Veterans Administration: Implementing the Principles of Person-Centered, Participation-Oriented Rehabilitation. [2020]

13. United States pubmed.ncbi.nlm.nih.gov

Military trauma training at civilian centers: a decade of advancements. [2015]

14. United States pubmed.ncbi.nlm.nih.gov

Polytrauma transitional rehabilitation programs: Comprehensive rehabilitation for community integration after brain injury. [2019]

15. United States pubmed.ncbi.nlm.nih.gov

Holism at the National Intrepid Center of Excellence (NICoE). [2013]